These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35155458)

  • 1. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma.
    Ma T; Wiggins CC; Kornatowski BM; Hailat RS; Clayburn AJ; Guo WL; Johnson PW; Senefeld JW; Klassen SA; Baker SE; Bruno KA; Fairweather D; Wright RS; Carter RE; Li C; Joyner MJ; Paneth NS
    Front Med (Lausanne); 2021; 8():707895. PubMed ID: 35155458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma.
    Ma T; Wiggins CC; Kornatowski BM; Hailat RS; Clayburn AC; Guo W; Johnson PW; Senefeld JW; Klassen SA; Baker SE; Bruno KA; Fairweather D; Wright RS; Carter RE; Li C; Joyner MJ; Paneth N
    medRxiv; 2021 Jan; ():. PubMed ID: 33501470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 May; 5(5):CD013600. PubMed ID: 37162745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013600. PubMed ID: 36734509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience.
    Joyner MJ; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Carter RE; Casadevall A
    medRxiv; 2020 Aug; ():. PubMed ID: 32817978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
    Karaba AH; Johnston TS; Beck E; Laeyendecker O; Cox AL; Klein SL; Sullivan DJ;
    mBio; 2023 Feb; 14(1):e0328722. PubMed ID: 36625657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.
    Hartman WR; Hess AS; Connor JP
    Transl Med Commun; 2020; 5(1):17. PubMed ID: 33072871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.
    Hartman WR; Hess AS; Connor JP
    Res Sq; 2020 Sep; ():. PubMed ID: 32793897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Successful Recovery of a Critically Ill COVID-19 Patient, Following the Combination of Therapeutic Plasma Exchange and Convalescent Plasma Transfusion: A Case Report.
    Novacescu AN; Duma G; Sandesc D; Sorescu T; Licker M
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early safety indicators of COVID-19 convalescent plasma in 5000 patients.
    Joyner MJ; Wright RS; Fairweather D; Senefeld JW; Bruno KA; Klassen SA; Carter RE; Klompas AM; Wiggins CC; Shepherd JR; Rea RF; Whelan ER; Clayburn AJ; Spiegel MR; Johnson PW; Lesser ER; Baker SE; Larson KF; Ripoll JG; Andersen KJ; Hodge DO; Kunze KL; Buras MR; Vogt MN; Herasevich V; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Van Buskirk CM; Winters JL; Stubbs JR; Paneth NS; Verdun NC; Marks P; Casadevall A
    J Clin Invest; 2020 Sep; 130(9):4791-4797. PubMed ID: 32525844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients].
    Chen S; Lu C; Li P; Wang L; Wang H; Yang Q; Chen-Li Y; Li J; Ma H; Sang Q; Xu L; Li J; Zhang Y; Kang Y; Xing L; Zhang G
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1293-1298. PubMed ID: 33463485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
    Li L; Zhang W; Hu Y; Tong X; Zheng S; Yang J; Kong Y; Ren L; Wei Q; Mei H; Hu C; Tao C; Yang R; Wang J; Yu Y; Guo Y; Wu X; Xu Z; Zeng L; Xiong N; Chen L; Wang J; Man N; Liu Y; Xu H; Deng E; Zhang X; Li C; Wang C; Su S; Zhang L; Wang J; Wu Y; Liu Z
    JAMA; 2020 Aug; 324(5):460-470. PubMed ID: 32492084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.